(Q38882776)

7 September 2017

0 references

Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials (English)

1 reference

7 September 2017

Xi Zhang

1

1 reference

7 September 2017

Yu-Ge Ran

series ordinal

2

1 reference

7 September 2017

Kun-Jie Wang

series ordinal

3

1 reference

7 September 2017

language of work or name

English

0 references

publication date

12 April 2016

1 reference

7 September 2017

1 reference

7 September 2017

12

1 reference

7 September 2017

12

1 reference

7 September 2017

1529-1539

1 reference

Targeting mTOR pathways in human malignancies

7 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

An expanding role for mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Everolimus-induced pneumonitis after drug-eluting stent implantation: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

The TSC-mTOR signaling pathway regulates the innate inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

The multifunctional role of mTOR in innate immunity: implications for transplant immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Sirolimus-associated pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Regulation of immune responses by mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0020

21 January 2018

Identifiers

DOI

10.2217/FON-2016-0020

1 reference

release_b3hy5bknkvautipcesgrydktn4

7 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b3hy5bknkvautipcesgrydktn4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference